Nomura Holdings Inc. Sells 15,669 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Nomura Holdings Inc. reduced its stake in shares of Elanco Animal Health Incorporated (NYSE:ELANGet Rating) by 0.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,517,977 shares of the company’s stock after selling 15,669 shares during the quarter. Nomura Holdings Inc. owned about 0.53% of Elanco Animal Health worth $65,797,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Herold Advisors Inc. bought a new position in Elanco Animal Health in the 1st quarter valued at $26,000. Tcwp LLC bought a new stake in Elanco Animal Health during the 1st quarter worth about $29,000. IndexIQ Advisors LLC bought a new stake in Elanco Animal Health during the 1st quarter worth about $32,000. CKW Financial Group lifted its position in Elanco Animal Health by 36.4% during the 1st quarter. CKW Financial Group now owns 1,500 shares of the company’s stock valued at $39,000 after purchasing an additional 400 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in shares of Elanco Animal Health by 147.8% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 1,556 shares of the company’s stock valued at $41,000 after purchasing an additional 928 shares during the last quarter. Institutional investors and hedge funds own 98.15% of the company’s stock.

Elanco Animal Health Stock Down 2.6 %

Shares of Elanco Animal Health stock opened at $15.37 on Wednesday. Elanco Animal Health Incorporated has a 1 year low of $13.94 and a 1 year high of $35.00. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.47 and a quick ratio of 1.47. The company has a market capitalization of $7.29 billion, a P/E ratio of -43.91, a price-to-earnings-growth ratio of 1.51 and a beta of 0.87. The business has a 50-day moving average of $18.31 and a two-hundred day moving average of $22.31.

Elanco Animal Health (NYSE:ELANGet Rating) last announced its earnings results on Monday, August 8th. The company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.26 by $0.10. The firm had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $1.18 billion. Elanco Animal Health had a negative net margin of 3.77% and a positive return on equity of 7.40%. The business’s quarterly revenue was down 8.0% on a year-over-year basis. During the same period last year, the company posted $0.28 EPS. As a group, equities analysts predict that Elanco Animal Health Incorporated will post 1.09 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on ELAN shares. Piper Sandler cut their price objective on shares of Elanco Animal Health from $22.00 to $21.00 and set a “neutral” rating on the stock in a report on Tuesday, August 16th. Barclays decreased their price objective on Elanco Animal Health from $32.00 to $18.00 and set an “equal weight” rating for the company in a research note on Monday. Stifel Nicolaus cut their target price on Elanco Animal Health from $30.00 to $22.00 and set a “hold” rating on the stock in a research note on Friday, June 24th. The Goldman Sachs Group lowered Elanco Animal Health from a “buy” rating to a “sell” rating and decreased their target price for the stock from $32.00 to $19.00 in a research report on Thursday, July 21st. Finally, Morgan Stanley downgraded shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $37.00 to $22.00 in a research report on Thursday, August 18th. One investment analyst has rated the stock with a sell rating and five have assigned a hold rating to the company. According to data from MarketBeat, Elanco Animal Health has an average rating of “Hold” and an average target price of $21.00.

Insider Buying and Selling

In other news, CEO Jeffrey N. Simmons purchased 30,000 shares of the business’s stock in a transaction dated Friday, September 9th. The shares were bought at an average cost of $14.54 per share, for a total transaction of $436,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 30,000 shares in the company, valued at approximately $436,200. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In other Elanco Animal Health news, CEO Jeffrey N. Simmons purchased 30,000 shares of the firm’s stock in a transaction dated Friday, September 9th. The stock was bought at an average cost of $14.54 per share, with a total value of $436,200.00. Following the purchase, the chief executive officer now directly owns 30,000 shares of the company’s stock, valued at $436,200. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Rajeev A. Modi acquired 6,700 shares of the business’s stock in a transaction dated Friday, September 9th. The stock was acquired at an average cost of $14.90 per share, for a total transaction of $99,830.00. Following the transaction, the insider now owns 41,157 shares of the company’s stock, valued at $613,239.30. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 56,700 shares of company stock valued at $839,630. Company insiders own 6.40% of the company’s stock.

Elanco Animal Health Profile

(Get Rating)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Recommended Stories

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELANGet Rating).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.